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Abstract
Background: Rural residents are less likely to receive screening for colorectal cancer (CRC) than urban residents.
However, the mechanisms underlying this disparity, especially among people aged 50–64 years old with private
health insurance, are not well understood. We examined the impact of travel time on stage at CRC diagnosis.
Methods: This retrospective cohort study used data from the Blue Cross and Blue Shield of Nebraska. Members of
this private insurance company aged 50–64 years, diagnosed with CRC during the period 2012–2016, and
continuously enrolled in the insurance plan for at least 6 months prior to CRC diagnosis, were selected for this
study. Using Google Maps, we estimated patients’ travel time from their home ZIP code to the ZIP code of their
colonoscopy provider. Using logistic regression, we analyzed the association between stage at CRC diagnosis, travel
time, use of preventive services (i.e., check-ups or counseling to prevent or detect illness at an early stage) and
patient characteristics.
Results: A total of 307 subjects met the inclusion criteria. People who had not used preventive services 6 months
prior to CRC diagnosis had 2.80 (95% CI, 1.00–7.90) times the odds of metastatic CRC compared to those who had
used these services. No statistically significant association was found between travel time and metastatic CRC
diagnosis (P = 0.99; 95% CI, 0.98–1.01).
Conclusions: The fact that 13% of the study population presented with metastatic CRC suggests some
noncompliance with preventive services such as screening guidelines. To increase screening uptake and reduce
metastatic cases, employers should offer incentives for their employees to make use of preventive services such as
CRC screening.
Keywords: Access to care, Colorectal cancer, Health services research, Geography, Private insurance

Background
Colorectal cancer (CRC) is the third most common cancer in the USA, preceded by lung and breast cancers in
women, and lung and prostate cancers in men. It is the
third leading cause of cancer death in the USA [1, 2].
Unlike breast cancer screening, screening for CRC not
only leads to early detection of cancer, but also can prevent cancer from occurring [3, 4]. The large decline in
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both incidence and mortality from CRC in the USA over
the past two decades has been attributed to the increased use of screening, especially colonoscopy [5].
Since the publication of the first guidelines for CRC
screening in 1995, the screening rate has steadily increased from 35 to 62.4% in 2015 [6]. In 1998, Congress
enacted a Medicare CRC screening benefit (i.e., Medicare is the federal health insurance program for individuals 65 years or older, certain younger individuals with
disabilities and individuals with end-stage renal disease),
but it was limited to fecal occult blood tests (FOBT) and
sigmoidoscopy for symptomatic or high-risk individuals,
and average-risk individuals with a positive FOBT who
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needed follow-up screening [7]. In 2001, the Medicare
coverage extended to average-risk individuals nationwide
for screening purposes [7, 8]. In 2010, the Affordable
Care Act (ACA), or the comprehensive health care reform law enacted in March 2010, required private health
insurance plans to cover preventive services recommended by the United States Preventive Services Task
Force and graded ‘A’ or ‘B’, including CRC screening,
with no out-of-pocket costs for members [9]. By 2011,
54 million privately insured Americans received additional preventive services coverage as required by the
ACA, which included colonoscopy screening, mammograms, and Pap smears [10].
Despite its known benefits, CRC screening uptake has
remained less than optimal. In 2015, only 65% of Americans eligible for screening were up to date on CRC screening [11], which is well below the 2014 Centers for Disease
Control and Prevention’s Colorectal Cancer Program target
of 80% [11], and the 70% goal set by Healthy People 2020
[12]. Further, individuals living in rural areas and other
medically underserved populations have lower rates of
CRC screening uptake. Studies have demonstrated that
rural residents are 30% less likely to receive CRC screening
than their urban counterparts [13, 14]. Individuals who are
underinsured or those with lower socioeconomic status are
also less likely to be up to date with CRC screening
[15, 16]. While previous research generally suggests lower
CRC screening rates among rural residents compared to
urban residents, the mechanism to explain this disparity
has not been well established. Nevertheless, the following
factors are thought to be involved: lower income levels [16,
17], a higher percentage of people who are underinsured or
uninsured [15, 18, 19], less awareness and understanding of
CRC risks and benefits of CRC screening [20, 21], lack of
physician recommendations on CRC screening [18, 22, 23],
and distance to a CRC screening facility [24, 25]. For
example, a population-based survey study conducted in
Nebraska found that rural residents are more likely to perceive screening cost as a barrier, and that CRC cannot be
prevented [20]. Unlike urban residents in Nebraska, rural
residents are 60% less likely to receive any CRC screening,
and 57% less likely to receive a colonoscopy [20].
Furthermore, the rural-urban disparities in access to
cancer services is a global phenomenon. Prior international
literature assessed the association between rural-urban status and cancer outcome [26]. For instance, Carriere et. Al.,
2018 conducted an international systematic review to assess
whether cancer survival among rural dwellers is less than
their urban counterpart. Despite heterogeneities between
studies (e.g., different definitions for rural-urban status and
diverse studied geographic regions), rural residents were 5%
less likely to survive cancer. Additionally, an Australian systematic review study found less mammography use
among rural population which also have contributed

to the lower breast cancer survival among women live
in rural areas [27].
Many previous CRC and breast cancer screening studies
were based on Medicare data, partly because it provides
claims data for nearly every US resident over the age of 65
years. It can also provide more objective and reliable evidence for cancer screening use compared to self-reported
survey data. However, substantial limitations of Medicare
data are the restriction of the population to adults older than
65 years old and the representation of only fee-for-service
Medicare beneficiaries. Given the consistently lower use of
CRC screening among adults between 50 and 64 years of
age [28], it is essential to elucidate factors associated with
lower CRC screening in this younger age group. This is especially important given the increased incidence of CRC
among individuals younger than 65 years of age [29].
Colonoscopy screening is associated with logistical
hurdles such as taking time off work, and having another
adult to accompany and transport the patient after the
procedure. This is necessary since most patients will
undergo conscious sedation and will miss a day of work
[30]. Additionally, the unpleasant experience of bowel
preparation before the procedure is a common obstacle
[20, 23, 31, 32]. These barriers are more likely to be a
perceived problem among rural residents since they are
more likely to have to travel longer distances to receive
a colonoscopy. According to the National Household
Travel Survey, 41% of trips taken by rural residents in
the US to receive medical or dental services were longer
than 30 min in duration, while only 25% of trips taken
by urban residents were longer than 30 min [33]. Distance to a screening facility has been shown to be a
significant barrier for rural patients [25, 34].
Well-established evidence has suggested a relationship
between screening and the prevention and early detection of CRC; therefore, this study was undertaken to assess the impact of travel time on stage at CRC diagnosis
among privately insured, rural-dwelling people aged
50–64. We hypothesize that shorter travel time to
colonoscopy facilities is associated with earlier stage
of diagnosis (i.e., non-metastatic diagnoses) of CRC
after accounting for other patient characteristics.

Methods
Data sources

This is a retrospective cohort study using data from Blue
Cross and Blue Shield of Nebraska (BCBSNE). BCBSNE is
the largest private health insurer in Nebraska, serving over
700,000 people [33]. Data comprises claims from inpatient
and outpatient facilities, and professional/office services,
and include diagnosis and procedural codes, dates of service and the five-digit ZIP code for the provider. The data
also contain members’ demographic information including age, gender, and their ZIP code of residence. BCBSNE
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captures members’ enrollment information including the
beginning and end date of coverage. Rural-Urban Community Area Codes (RUCA) data and Google Maps were
used to determine rurality and travel time [35, 36].
RUCA uses the U.S. Census Bureau’s Urbanized Area
(UA) and Urbanized Cluster (UC) definitions supplemented with information on work commute and population density to characterize all of the census tracts
regarding their rural and urban status [36]. The classification assigns metropolitan (i.e., primary commuting
flow within an UA), micropolitan (i.e., large rural or
primary flow within an UC of 10,000 to 49,999 individuals), small town (i.e., primary flow within an UC of
2500–9999 individuals) and rural commuting areas (i.e.,
primary flow to a tract outside a UA or UC) with numbers between 1 and 10. These numbers are subdivided
into 21 secondary codes based on commuting flows. Although the original RUCA classification was based on
census tract, it uses the ZIP code as its geographic unit.
The latest RUCA codes are based on the 2010 decennial
census and the 2006–2010 American Community Survey.
Furthermore, Google maps offer accurate driving
directions between places at no cost. A program was
developed (open-source programming language that is
available on SAS) to make repeated calls to Google to
obtain travel time information for any number of locations [37]. Subsequently, the program was tested using a
nationally representative sample that cover 66,000 locations in the fifty states, the District of Columbia and
Puerto Rico [35]. The program developer found a high
correlation of Google maps with straight-line distance
(r2 = 0.96) but with superior travel time estimate. While
other GIS mapping systems offer greater sophistications
and precision, it is at the expense of acquiring and managing specialized GIS software. The additional precision
offered by other GIS, doesn’t provide more value to the research question raised on this study (i.e., nonemergency
medical care) and to the state of Nebraska [35, 38].

least one inpatient or two outpatient claims with a
primary diagnosis of CRC at two different visits. See the
Appendix 1 for the codes used to identify the diagnosis of
CRC [41]. We excluded members who were older than 65
years of age because the BCBSNE data likely did not
contain claims for all of their Medicare-covered health
services. We also excluded members with prior cancers
(i.e., cancers at sites other than the colon/rectum) to ensure that the secondary malignant neoplasm originated
from CRC [39, 40]. Any members residing outside the
state of Nebraska were excluded because the study is
confined to the residents of Nebraska.
Study variables
Patient characteristics

The beginning and end dates of coverage and services
were extracted from patients’ enrollment files. Patient
demographics including age, gender, and five-digit ZIP
code of residence were extracted from their membership
file. Utilization and clinical variables such as stage at
diagnoses and preventive services use were derived from
international classification of disease fields, and current
procedural terminology fields from the claims file.
A dichotomous yes/no variable was also created to
reflect members’ use of preventive services in the 6
months preceding the CRC diagnosis. Preventive
services were defined as any health services such as
check-ups or counseling to prevent or detect illness at
an early stage when treatment is more viable [42]. Codes
used to identify preventive services are detailed in the
Appendix 2 [43]. In this study, individuals with at least
one claim indicating the use of preventive services
within 6 months prior to CRC diagnosis were considered
to have used preventive services. Initial prevention medicine for a new patient, or periodic prevention medicine
for an established patient aged 40–64 years old were
examples of the codes used [44].
Travel time measurement

Study population

Individuals included in the study were members of
BCBSNE between January 1st, 2012, and June 30th,
2016; aged 50–64 years old with no prior CRC-related
claims in the last 3 months; no prior cancers of any kind
during the 6 months preceding the index diagnosis
[39, 40]: The International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes 140–1529,1550–1958, or 1991–200; ICD-10-CM
diagnosis codes C000-C179, C220-C768, or C80-C83; and
were enrolled in BCBSNE for at least 6 months prior to
the month in which their first diagnosis of CRC was identified. Figure 1 illustrates the eligibility criteria and the
number of patients excluded for each criterion. Individuals
were considered to be diagnosed with CRC if they had at

A patient’s ‘index’ colonoscopy was designated as the first
time a patient had undergone a colonoscopy within 4
months prior to their CRC diagnosis. This colonoscopy
was the basis on which both members’ and providers’ ZIP
codes were defined to calculate travel time. The provider’s
ZIP code was defined as that on the date of the index
colonoscopy, and the member’s ZIP code as that for their
place of residence when receiving the index colonoscopy.
Travel time was calculated by measuring the time in
minutes between the geographic centroid of each member’s ZIP code of residence and the provider’s ZIP code
at the time of service. Travel time calculations were
made using the Google Maps web page, using the SAS
FILENAME URL method in SAS [35]. The method has
a high correlation with straight-line distance (r2 = 0.96),
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Fig. 1 Eligibility criteria for the study population

but with a superior travel time estimate [35]. We
measured travel time as a continuous variable, as well as
four categories based on quartile distribution. For the
rural-urban status definition, we used RUCA codes to
assign each member’s residential status based on their
residential ZIP code. Subsequently, we used these codes
to classify members by rural–urban status using
“Categorization C” as suggested by the publisher [45].
This categorization aggregates RUCA codes into urban
and rural codes. The urban codes consist of a metropolitan area core, micropolitan or small-town high-commuting areas, or rural areas with a secondary
commuting flow of 30 to 49% within an urban area. The
rural codes consist of a micropolitan area core with
secondary flow of 10–29% to an urban area, small-town,
low-commuting areas, or rural areas with commuting to
urban cluster areas.
Outcome variables

The primary outcome was the stage at CRC diagnosis,
classified as metastatic versus non-metastatic CRC. This
was based on the initial CRC diagnosis identified in the

claims data. The following diagnosis codes were used to
identify patients diagnosed with metastatic CRC at the
time of initial cancer diagnosis: ICD-9-CM diagnosis
codes 196.0, 196.1, 196.3, 196.5, 197.0–197.4, 197.6197.7,
198.0–198.8 or 199.0; and ICD-10-CM diagnosis codes
C770, C771, C773, C774, C780.0-C784, C786, C787,
C788, C790–C798 or C80. The first date of metastatic
diagnosis was assigned as the ‘index’ metastatic diagnosis
[39]. Those patients who did not have a metastatic CRC
diagnosis at the time of initial cancer diagnosis were
considered non-metastatic.
Data analysis

Age, gender, rural-urban status, colonoscopy use within
4 months prior to CRC diagnosis, use of preventive services, and travel time were compared between
metastatic and non-metastatic groups using Wilcoxon’s
rank-sum test for continuous variables, and the
Chi-square (X2) test for categorical variables. Wald tests
were used to assess the significance of predictors. We
used the fractional polynomial method to examine any
non-linear relationships between the log odds of
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metastatic diagnosis and continuous variables. We
inspected the curves of the predictors against the dichotomous response and used the likelihood ratio test for improvement in fit against the assumed linear relationship.
Lastly, we conducted a multivariate analysis to assess the
relationship between travel time and metastatic CRC diagnosis, adjusting for gender, rural-urban status, and use of
preventive services. All tests were two-tailed and with α =
0.05. We used SAS statistical software version 9.4 (SAS
Institute Inc. Cary, NC) to conduct all analyses.

Results
The application of the inclusion and exclusion criteria
resulted in a cohort of 307 patients (Fig. 1). Of the 307
members who met our eligibility criteria, we were able to
identify that 66% (n = 204) had undergone a colonoscopy
within the 4 months prior to CRC diagnosis; 13% (n = 27)
of these presented with metastatic CRC. There were no
differences in the measured characteristics between patients who used colonoscopy within the 4 months prior to
CRC diagnosis and those who did not. Table 1 shows the
characteristics of BCBSNE members diagnosed with CRC
who made a claim for colonoscopy within the 4 months
prior to CRC diagnosis. There were no significant
differences between metastatic and non-metastatic cases.
Most cases were diagnosed during the years 2013 and
2014 in both metastatic and non-metastatic groups. While
the average number of months of enrollment before CRC
diagnosis were similar between metastatic and non-metastatic cases (13.0 versus 13.53), the median number of
months of enrollment was slightly higher among the
metastatic group (26.0 versus 22.0).
Table 2 shows our analyses of the association between
travel time and metastatic CRC among members who had
undergone colonoscopy within 4 months prior to their
diagnosis (n = 204). Mean and median travel times were
very similar between the metastatic (mean = 34.85 min)
and non-metastatic (mean = 33.38 min) groups. Among
these members, 25% traveled a distance of a maximum of
6 miles, 50% traveled a distance of a maximum of 15 miles,
and 75% traveled a distance of a maximum of 31 miles.
While the median distance traveled by rural patients was
26 miles, urban patients traveled a median of 8 miles to
get to a colonoscopy facility. For those who did not have
claims for preventive services, the odds of being diagnosed
with metastatic CRC was 2.80 (95% CI: 1.00–7.90) times
greater than those who had claims for preventive services
prior to CRC diagnosis.
Discussion
The motivation to conduct this study was based on the
notion that, unlike the Medicare population, people aged
50–64 years old more often have barriers related to work
schedules, and are therefore less inclined to travel to a
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colonoscopy facility to be screened, leading to more
frequent presentation with metastatic CRC [46–48]. Although our focus was primarily on the impact of rurality
and travel times, we also examined the roles of demographic factors and use of preventive services; the characteristics of people in rural populations are different
from those of the urban population, and access to
services is of concern [20, 25, 49, 50].
We found no significant association between rural residency and late-stage at CRC diagnosis, which is comparable
to results from recent studies that used cancer registry data
from Iowa, Nebraska, and Georgia [50–52], with exceptions
from a study that used 1998–2002 Illinois cancer registry
data [53]. Also, the current study did not find a significant
association between travel time and late-stage diagnosis.
Again, the findings from this study generally confirm the
results from the studies that used cancer registry data
[51, 54]. Also, survey data generally indicate a lower
adherence rate of CRC screening among rural residents compared to urban residents [13, 55].
Another explanation for the discrepancy between the
survey studies and our results could be attributed to the
differences between registry and claims data versus survey data. Survey data include insured, uninsured or
underinsured individuals, while our sample consists of
only insured individuals. Survey data can also suffer
from potential biases (e.g., recall bias, social desirability
bias), while registry data, and claims-based data, are
more valid because of the accuracy required when
reporting for a registry, and because claim’s reimbursement is dependent on patients’ health encounters. Additionally, registry data covers the entire state of
Nebraska. While our sample is from BCBSNE, which is
the largest private health insurance in Nebraska [56], the
sample does not represent the entire privately insured
population in Nebraska, nor the uninsured population.
Another likely explanation is that there are widely varying degrees of rurality in different states. Rural Nebraska
is very different from rural Alaska, or rural Kentucky,
for example, where the differences between urban and
rural populations in terms of use of health services may
be much greater.
Our results indicate the key role of preventive services
in the prevention or early detection of CRC. We found
that patients who did not use preventive services within
the 6 months prior to their CRC diagnosis were two
times more likely to be diagnosed as having metastatic
CRC compared to those who had availed of such services. This result likely reflects the notion that cancer
screening communication between the patient and the
provider may occur during an annual checkup or other
routine care settings [57–59]. Not surprisingly, it also
likely demonstrates that preventive visits are the main
referral source for screening colonoscopies, whereas
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Table 1 Characteristics of BCBSNE members diagnosed with CRC who made a colonoscopy claim within 4 months prior to their
CRC diagnosis (n = 204)
Characteristics

Total (204)

Metastatic (27)

Non-metastatic (177)

N

%

N

%

N

%

P

Mean (SD)

57.50

4.0

57.56

4.56

57.48

4.15

0.91

Median (SD)

58.0

7.0

57.0

8.0

58.0

7.0

Age

50–54

56

27.0

7

26.0

49

28.0

55–60

92

45.0

12

44.0

80

45.0

≥ 61

56

28.0

8

30.0

48

27.0

Male

112

54.90

17

63.0

95

53.67

Female

92

45.10

10

37.0

82

46.33

Rural

110

53.92

11

41.0

99

56.0

Urban

94

46.08

16

59.0

78

44.0

Mean (SD)

33.58

40.0

34.85

51.53

33.38

38.12

Median (SD)

19.0

27.0

18.0

17.0

19.0

28.0

Gender
0.37

Member location
0.14

Travel time (min)

Q1

11

–

13

–

11

–

Q2

19

–

18

–

19

–

Q3

38

–

30

–

39

–

Q4

227

–

223

–

227

–

29.0

43.0

30.0

58.0

29.0

40.50

0.74

Travel distance, (miles)
Mean (SD)
Median (SD)

13.0

26.0

13.0

19.0

13.0

28.50

Q1

5.0

–

5.0

–

4.50

–

Q2

13.0

–

13.0

–

13.0

–

Q3

31.0

–

24.0

–

33.0

–

Q4

251.0

–

251.0

–

234.0

–

0.74

PCP access
PCP/10,000 mean

11.03

8.10

12.33

12.08

10.82

7.31

PCP/10,000 median

10.08

8.51

7.82

13.58

10.24

8.19

2012

33

16.0

7

26.0

26

15.0

2013

50

25.0

4

15.0

46

26.0

2014

62

30.0

11

41.0

51

29.0

2015

39

19.0

5

18.0

34

19.0

2016

20

10.0

0

0

20

11.0

0.95

Year of CRC diagnosis

Months of enrollment before CRC diagnosis
Mean (SD)

26

13.50

25

13.0

26

13.53

Median (IQR)

26

22.0

28

26.0

25

22.0

acute visits for CRC-related symptoms are the main referral source for diagnostic colonoscopies. Accordingly,
non-distance barriers that can prevent or delay the
receipt of preventive services should be alleviated. For

instance, to encourage visits to a primary care physician,
insurers/employers should consider removing cost-sharing during the initial CRC screening visits. An example
of a potential cost that might incur during the initial
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Table 2 Logistic regressions of CRC patients who made a
colonoscopy claim within 4 months prior to their CRC diagnosis
(n = 204)
Characteristics
Age

Univariate Model

Multivariate Model

Odds ratio (95% CI)

P

1.004 (0.91–1.01)

0.91

Odds ratio (95% CI)

Gender
Male

1.0

Female

0.68 (0.29–1.57)

1.0
0.37

0.76 (0.32–1.80)

Member location
Rural

1.0

1.0

Urban

1.84 (0.82–4.20)

0.14

2.14 (0.87–5.30)

1.001 (0.99–1.01)

0.74

0.99 (0.98–1.01)

0.04

2.80 (1.00–7.90)

Travel time (min)
Mean
Preventive services
Yes

1.0

No

2.81 (1.02–7.77)

1.0

The association between travel time and metastatic CRC diagnosis is adjusted
for gender, rural–urban status, and use of preventive services

visit is polyp removal [60, 61]. Co-insurance should also
be removed from those undergoing follow-up
colonoscopies after positive stool-based screening tests.
Compared to the older population (aged ≥65 years),
CRC in the younger population appears to be a more
aggressive disease [62–67]. It is more prevalent in the
distal colon or rectum, tends to be poorly differentiated,
more likely to be of mucinous and signet ring feature,
and is typically diagnosed at later stages. These characteristics have been associated with a fast-growing CRC
[68–70]. In addition to differences in molecular biology,
the more aggressive nature among younger patients
could be a result of lack of screening, non-compliance
with screening guidelines, or failure to recognize and assess colonic symptoms among younger subjects [29, 69,
71, 72]. Non-compliance with colonoscopy screening has
been linked to logistical barriers such as scheduling the
colonoscopy procedure, or taking time off work to
undergo colonoscopy, which is more common among
the working-age population [73, 74].
Some limitations should be noted when interpreting the
findings. First, we excluded 33.6% of the study sample for
the travel time analysis because we were not able to identify
whether these individuals had made colonoscopy claims
within the 4 months prior to their CRC diagnosis. It is
possible that some of these patients were diagnosed at the
time of surgery because of an obstructed colon. Another
possible explanation was that some of these cases could
have been initially diagnosed with CRC prior to the study
period, and then later presented with metastatic CRC that
was diagnosed via radiologic imaging. Nonetheless, excluded cases were not significantly different from those
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included in all measured characteristics in this study.
Second, our population is limited to individuals with private
insurance from BCBSNE who live in the state of Nebraska,
and our results may therefore not generalize to populations
located in different states or with different types of insurance. Nonetheless, Nebraskans represent the US population
relatively well in terms of sociodemographic characteristics
except Nebraska has a higher proportion of whites than the
U.S. average (79.0% vs. 60.7%) [75]. Third, we were unable
to determine whether members bypassed the closest colonoscopy facility and voluntarily traveled longer distances to
undergo screening at other facilities because BCBSNE data
does not include all colonoscopy facilities in the state of
Nebraska. Fourth, previous studies show that SES is proportionally associated with access to health services use
[76]. In the current study, we were unable to control for
the effect of SES. Nonetheless, the studied population is
comprised of privately-insured population who we assumed
is a homogenous population. We considered insurance status a proxy to SES because it has been found to be important in determining health outcomes in terms of access to
health care [76]. According to US census data, 93.4% of
Nebraskans have obtained a high school diploma and 59%
of the households with median earnings of ≥ $45,000 [77].
Fifth, findings should be interpreted with cautions since the
6 months period for identifying preventive services use
might not entirely capture the health behavior of an individual. For instance, one might use more health services
only during or after an acute illness and thus, will be less
likely to be captured within the window of 6 months.
Ideally, we should examine the preventive services use
within longer period of CRC diagnosis [44, 78]. Finally, it is
possible that the current study is underpowered to find
association between travel-time and stage at diagnosis.

Conclusions
This study did not find an association between the travel
time taken for patients to reach colonoscopy facilities
and the metastatic stage of their cancer at diagnosis. The
fact that 13% of this privately insured working-age population presented with metastatic CRC suggests some
non-compliance with screening guidelines. It is also possible that in this young cohort, some cases presented
with an aggressive and fast-growing disease, with the potential development of metastatic CRC between screening colonoscopies. Nevertheless, it is possible that this
working-age population faces logistic barriers that prevent them from taking time off work to undergo screening. To increase screening use and reduce cases of
metastatic CRC, employers should offer incentives (e.g.,
removing cost-sharing during initial visits, or for
follow-up colonoscopy among individuals with FOBT
positive test) for their employees to undergo preventive
services such as CRC screening.
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Appendix 1
Table 3 ICD codes used in identifying the diagnosis of CRC
ICD code-9 and 10

Description

153.0/C183

Malignant neoplasm of hepatic flexure

153.1/C184

Malignant neoplasm of transverse colon

153.2/C186

Malignant neoplasm of descending colon

153.3/C187

Malignant neoplasm of sigmoid colon

153.4/C180

Malignant neoplasm of cecum

153.6/C182

Malignant neoplasm of ascending colon

153.7/C185

Malignant neoplasm of splenic flexure

153.8/C188

Malignant neoplasm of other specified sites
of large intestine

153.9/C189

Malignant neoplasm of colon, unspecified site

154.0/C19

Malignant neoplasm of rectosigmoid junction

154.1/C20

Malignant neoplasm of rectum

154.8/C218

Malignant neoplasm of other sites of rectum,
rectosigmoid junction, and anus
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General medical examination,
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Confirms pap smear test

Description
initial preventive
medicine new
patient 40-64 yrs
periodic preventive
med established
patient 40-64 yrs

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1
Department of Population Health Research, King Abdullah International
Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for
Health Sciences, P.O. Box 3660, Riyadh 11481, 1515, Saudi Arabia.
2
Department of Epidemiology, University of Iowa College of Public Health,
145 N. Riverside Drive, Iowa City, Iowa 52242, USA. 3Department of
Biostatistics, University of Nebraska Medical Center, College of Public Health,
984375 Nebraska Medical Center, Omaha, NE 68198–4395, USA. 4Department
of Epidemiology, University of Nebraska Medical Center, College of Public
Health, 984395 Nebraska Medical Center, Omaha, NE 68198–4395, USA. 5City
University of New York School of Medicine, Community Health and Social
Medicine, 160 Convent Avenue, New York, NY 10031, USA.
Received: 17 August 2018 Accepted: 12 March 2019

References
1. Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, Boscoe
FP, Cronin KA, Lake A, Noone AM, et al. Annual Report to the Nation on the
Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes
by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst. 2015;107(6):djv048.
2. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J
Clin. 2014;64(2):104–17.
3. Allison JE. The effect of fecal occult-blood screening on the incidence of
colorectal cancer. N Engl J Med. 2001;344(13):1022 author reply 1023.
4. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye
JD, Schapiro M, Bond JH, Panish JF. Prevention of colorectal cancer by
colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J
Med. 1993;329(27):1977–81.

Alyabsi et al. BMC Health Services Research

5.
6.

7.

8.

9.

10.

11.

12.

13.

14.
15.

16.

17.

18.
19.

20.

21.
22.
23.

24.
25.

26.

27.

28.

29.

(2019) 19:172

Welch HG, Robertson DJ. Colorectal Cancer on the decline--why screening
Can't explain it all. N Engl J Med. 2016;374(17):1605–7.
White A, Thompson TD, White MC, Sabatino SA, de Moor J, Doria-Rose PV,
Geiger AM, Richardson LC. Cancer screening test use - United States, 2015.
MMWR Morb Mortal Wkly Rep. 2017;66(8):201–6.
Medicare Claims Processing [https://www.cms.gov/Regulations-andGuidance/Guidance/Transmittals/downloads/r52cp.pdf]. Accessed 12 Dec
2017.
Phillips KA, Liang SY, Ladabaum U, Haas J, Kerlikowske K, Lieberman D, Hiatt
R, Nagamine M, Van Bebber SL. Trends in colonoscopy for colorectal cancer
screening. Med Care. 2007;45(2):160–7.
Coverage of Colonoscopies Under the Affordable Care Act's Prevention
Benefit. [https://www.kff.org/health-costs/report/coverage-of-colonoscopiesunder-the-affordable-care/]. Accessed 12 Dec 2017.
Sommers B, Wilson L. Fifty-four million additional Americans are
receiving preventive services without cost-sharing under the affordable
care act. In: Issue Brief, Office of the Assistant Secretary for Planning
and Evaluation: In; 2012.
Klabunde C, Joseph D, King J, White A, Plescia M. Vital Signs: Colorectal
Cancer Screening Test Use — United States, 2012. In: Morbidity and
Mortality Weekly Report (MMWR). vol. 62; 2013. p. 881–8.
Centers for Disease Control and Prevention. Vital signs: colorectal cancer
screening, incidence, and mortality--United States, 2002-2010. MMWR Morb
Mortal Wkly Rep. 2011;60(26):884–9.
Anderson AE, Henry KA, Samadder NJ, Merrill RM, Kinney AY. Rural vs urban
residence affects risk-appropriate colorectal cancer screening. Clin
Gastroenterol Hepatol. 2013;11(5):526–33.
Ojinnaka CO, Choi Y, Kum HC, Bolin JN. Predictors of colorectal Cancer
screening: does rurality play a role? J Rural Health. 2015;31(3):254–68.
Meissner HI, Breen N, Klabunde CN, Vernon SW. Patterns of colorectal
cancer screening uptake among men and women in the United States.
Cancer Epidemiol Biomark Prev. 2006;15(2):389–94.
Pollack LA, Blackman DK, Wilson KM, Seeff LC, Nadel MR. Colorectal cancer
test use among Hispanic and non-Hispanic U.S. populations. Prev Chronic
Dis. 2006;3(2):A50.
Carlos RC, Underwood W, Fendrick AM, Bernstein SJ. Behavioral
associations between prostate and colon cancer screening. J Am Coll
Surg. 2005;200(2):216–23.
Honda K. Factors associated with colorectal cancer screening among the US
urban Japanese population. Am J Public Health. 2004;94(5):815–22.
Tang TS, Solomon LJ, McCracken LM. Barriers to fecal occult blood testing
and sigmoidoscopy among older Chinese-American women. Cancer Pract.
2001;9(6):277–82.
Hughes AG, Watanabe-Galloway S, Schnell P, Soliman AS. Rural-urban
differences in colorectal Cancer screening barriers in Nebraska. J
Community Health. 2015;40(6):1065–74.
Klabunde CN, Schenck AP, Davis WW. Barriers to colorectal cancer screening
among Medicare consumers. Am J Prev Med. 2006;30(4):313–9.
Gilbert A, Kanarek N. Colorectal cancer screening: physician recommendation
is influential advice to Marylanders. Prev Med. 2005;41(2):367–79.
Janz NK, Wren PA, Schottenfeld D, Guire KE. Colorectal cancer
screening attitudes and behavior: a population-based study. Prev Med.
2003;37(6 Pt 1):627–34.
Bennett KJ, Probst JC, Bellinger JD. Receipt of cancer screening services:
surprising results for some rural minorities. J Rural Health. 2012;28(1):63–72.
Coughlin SS, Thompson TD. Colorectal cancer screening practices among
men and women in rural and nonrural areas of the United States, 1999. J
Rural Health. 2004;20(2):118–24.
Carriere R, Adam R, Fielding S, Barlas R, Ong Y, Murchie P. Rural dwellers are
less likely to survive cancer - an international review and meta-analysis.
Health Place. 2018;53:219–27.
Leung J, McKenzie S, Martin J, McLaughlin D. Effect of rurality on screening
for breast cancer: a systematic review and meta-analysis comparing
mammography. Rural Remote Health. 2014;14(2):2730.
Siegel, R.L., Miller, K.D., Fedewa, S.A., Ahnen, D.J., Meester, R.G., Barzi, A. and
Jemal, A., 2017. Colorectal cancer statistics, 2017. CA: a cancer journal for
clinicians, 67(3), pp.177-93.
Ahnen DJ, Wade SW, Jones WF, Sifri R, Mendoza Silveiras J, Greenamyer J,
Guiffre S, Axilbund J, Spiegel A, You YN. The increasing incidence of youngonset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89(2):216–24.

Page 9 of 10

30. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash
C, Giardiello FM, Glick S, Levin TR, et al. Screening and surveillance for the
early detection of colorectal cancer and adenomatous polyps, 2008: a joint
guideline from the American Cancer Society, the US multi-Society task force
on colorectal Cancer, and the American College of Radiology. CA Cancer J
Clin. 2008;58(3):130–60.
31. Harewood GC, Wiersema MJ, Melton LJ. A prospective, controlled
assessment of factors influencing acceptance of screening colonoscopy. Am
J Gastroenterol. 2002;97(12):3186–94.
32. Walsh JM, Kaplan CP, Nguyen B, Gildengorin G, McPhee SJ, Pérez-Stable
EJ. Barriers to colorectal cancer screening in Latino and Vietnamese
Americans. Compared with non-Latino white Americans. J Gen Intern
Med. 2004;19(2):156–66.
33. Probst JC, Laditka SB, Wang JY, Johnson AO. Effects of residence and race
on burden of travel for care: cross sectional analysis of the 2001 US National
Household Travel Survey. BMC Health Serv Res. 2007;7:40.
34. James TM, Greiner KA, Ellerbeck EF, Feng C, Ahluwalia JS. Disparities in
colorectal cancer screening: a guideline-based analysis of adherence. Ethn
Dis. 2006;16(1):228–33.
35. Boscoe FP, Henry KA, Zdeb MS. A Nationwide Comparison of Driving Distance
Versus Straight-Line Distance to Hospitals. Prof Geogr. 2012;64(2):188–96.
36. Using RUCA Data [http://depts.washington.edu/uwruca/ruca-uses.php].
Accessed 7 Mar 2017.
37. Driving Distances and Drive Times using SAS and Google Maps [http://
www.sascommunity.org/wiki/Driving_Distances_and_Drive_Times_using_
SAS_and_Google_Maps]. Accessed 7 Mar 2017.
38. Lee RC. Current approaches to shortage area designation. J Rural Health.
1991;7(4 Suppl):437–50.
39. Paramore LC, Thomas SK, Knopf KB, Cragin LS, Fraeman KH. Estimating costs
of care for patients with newly diagnosed metastatic colorectal cancer. Clin
Colorectal Cancer. 2006;6(1):52–8.
40. Song X, Zhao Z, Barber B, Gregory C, Schutt D, Gao S. Characterizing
medical care by disease phase in metastatic colorectal cancer. Am J Manag
Care. 2011;17 Suppl 5 Developing:SP20–25.
41. Setoguchi S, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S.
Agreement of diagnosis and its date for hematologic malignancies and
solid tumors between medicare claims and cancer registry data. Cancer
Causes Control. 2007;18(5):561–9.
42. What is Preventive Care? [https://www.cdc.gov/prevention/]. Accessed 10
Mar 2017.
43. Fenton JJ, Franks P, Reid RJ, Elmore JG, Baldwin LM. Continuity of care and
cancer screening among health plan enrollees. Med Care. 2008;46(1):58–62.
44. Fenton JJ, Cai Y, Weiss NS, Elmore JG, Pardee RE, Reid RJ, Baldwin LM.
Delivery of cancer screening: how important is the preventive health
examination? Arch Intern Med. 2007;167(6):580–5.
45. RUCA Data [http://depts.washington.edu/uwruca/ruca-codes.php]. Accessed
7 Mar 2017.
46. Cokkinides VE, Chao A, Smith RA, Vernon SW, Thun MJ. Correlates of
underutilization of colorectal cancer screening among U.S. adults, age 50
years and older. Prev Med. 2003;36(1):85–91.
47. Tessaro I, Mangone C, Parkar I, Pawar V. Knowledge, barriers, and predictors
of colorectal cancer screening in an Appalachian church population. Prev
Chronic Dis. 2006;3(4):A123.
48. Vernon SW. Participation in colorectal cancer screening: a review. J Natl
Cancer Inst. 1997;89(19):1406–22.
49. Sankaranarayanan J, Watanabe-Galloway S, Sun J, Qiu F, Boilesen EC,
Thorson AG. Age and rural residence effects on accessing colorectal cancer
treatments: a registry study. Am J Manag Care. 2010;16(4):265–73.
50. Sankaranarayanan J, Watanabe-Galloway S, Sun J, Qiu F, Boilesen E, Thorson
AG. Rurality and other determinants of early colorectal cancer diagnosis in
Nebraska: a 6-year cancer registry study, 1998-2003. J Rural Health. 2009;
25(4):358–65.
51. Charlton ME, Matthews KA, Gaglioti A, Bay C, McDowell BD, Ward MM, Levy
BT. Is travel time to colonoscopy associated with late-stage colorectal
Cancer among Medicare beneficiaries in Iowa? J Rural Health. 2016;32(4):
363–73.
52. Hines R, Markossian T, Johnson A, Dong F, Bayakly R. Geographic residency
status and census tract socioeconomic status as determinants of colorectal
cancer outcomes. Am J Public Health. 2014;104(3):e63–71.
53. McLafferty S, Wang F. Rural reversal? Rural-urban disparities in late-stage
cancer risk in Illinois. Cancer. 2009;115(12):2755–64.

Alyabsi et al. BMC Health Services Research

(2019) 19:172

54. Scoggins JF, Fedorenko CR, Donahue SM, Buchwald D, Blough DK, Ramsey
SD. Is distance to provider a barrier to care for medicaid patients with
breast, colorectal, or lung cancer? J Rural Health. 2012;28(1):54–62.
55. Cole AM, Jackson JE, Doescher M. Urban-rural disparities in colorectal
cancer screening: cross-sectional analysis of 1998-2005 data from the
centers for disease Control's behavioral risk factor surveillance study. Cancer
Med. 2012;1(3):350–6.
56. Company profile [https://www.nebraskablue.com/about/company-profile/
history]. Accessed 10 May 2017.
57. Dolan NC, Ramirez-Zohfeld V, Rademaker AW, Ferreira MR, Galanter WL,
Radosta J, Eder MM, Cameron KA. The effectiveness of a physician-only and
physician-patient intervention on colorectal Cancer screening discussions
between providers and African American and Latino patients. J Gen Intern
Med. 2015;30(12):1780–7.
58. Laiyemo AO, Adebogun AO, Doubeni CA, Ricks-Santi L, McDonald-Pinkett S,
Young PE, Cash BD, Klabunde CN. Influence of provider discussion and
specific recommendation on colorectal cancer screening uptake among U.S.
adults. Prev Med. 2014;67:1–5.
59. Mosen DM, Feldstein AC, Perrin NA, Rosales AG, Smith DH, Liles EG,
Schneider JL, Meyers RE, Elston-Lafata J. More comprehensive discussion of
CRC screening associated with higher screening. Am J Manag Care. 2013;
19(4):265–71.
60. Green BB, Coronado GD, Devoe JE, Allison J. Navigating the murky waters
of colorectal cancer screening and health reform. Am J Public Health. 2014;
104(6):982–6.
61. Peterse EFP, Meester RGS, Gini A, Doubeni CA, Anderson DS, Berger FG,
Zauber AG, Lansdorp-Vogelaar I. Value of waiving coinsurance for colorectal
Cancer screening in Medicare beneficiaries. Health Aff (Millwood). 2017;
36(12):2151–9.
62. Domergue J, Ismail M, Astre C, Saint-Aubert B, Joyeux H, Solassol C, Pujol H.
Colorectal carcinoma in patients younger than 40 years of age. Montpellier
Cancer institute experience with 78 patients. Cancer. 1988;61(4):835–40.
63. Dozois EJ, Boardman LA, Suwanthanma W, Limburg PJ, Cima RR, Bakken JL,
Vierkant RA, Aakre JA, Larson DW. Young-onset colorectal cancer in patients
with no known genetic predisposition: can we increase early recognition
and improve outcome? Medicine (Baltimore). 2008;87(5):259–63.
64. Fairley TL, Cardinez CJ, Martin J, Alley L, Friedman C, Edwards B, Jamison P.
Colorectal cancer in U.S. adults younger than 50 years of age, 1998-2001.
Cancer. 2006;107(5 Suppl):1153–61.
65. Lee PY, Fletcher WS, Sullivan ES, Vetto JT. Colorectal cancer in young
patients: characteristics and outcome. Am Surg. 1994;60(8):607–12.
66. Schellerer VS, Merkel S, Schumann SC, Schlabrakowski A, Förtsch T,
Schildberg C, Hohenberger W, Croner RS. Despite aggressive histopathology
survival is not impaired in young patients with colorectal cancer : CRC in
patients under 50 years of age. Int J Color Dis. 2012;27(1):71–9.
67. You YN, Xing Y, Feig BW, Chang GJ, Cormier JN. Young-onset colorectal
cancer: is it time to pay attention? Arch Intern Med. 2012;172(3):287–9.
68. Alici S, Aykan NF, Sakar B, Bulutlar G, Kaytan E, Topuz E. Colorectal cancer in
young patients: characteristics and outcome. Tohoku J Exp Med. 2003;
199(2):85–93.
69. Ballester V, Rashtak S, Boardman L. Clinical and molecular features of youngonset colorectal cancer. World J Gastroenterol. 2016;22(5):1736–44.
70. O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do
young colon cancer patients have worse outcomes? World J Surg. 2004;
28(6):558–62.
71. Society AC. Colorectal Cancer Facts & Figures, 2017–2019. Atlanta: American
Cancer Society;2017; 2017.
72. Trivers KF, Shaw KM, Sabatino SA, Shapiro JA, Coates RJ. Trends in colorectal
cancer screening disparities in people aged 50-64 years, 2000-2005. Am J
Prev Med. 2008;35(3):185–93.
73. Denberg TD, Melhado TV, Coombes JM, Beaty BL, Berman K, Byers TE,
Marcus AC, Steiner JF, Ahnen DJ. Predictors of nonadherence to screening
colonoscopy. J Gen Intern Med. 2005;20(11):989–95.
74. Subramanian S, Klosterman M, Amonkar MM, Hunt TL. Adherence with
colorectal cancer screening guidelines: a review. Prev Med. 2004;38(5):536–50.
75. United States Census Bureau: QuickFacts Nebraska. 2017.
76. Singer BH, Ryff CD, Council NR: The influence of inequality on Health
Outcomes. 2001.
77. U.S. Census Bureau: Selected economic characteristics, 2013–2017 American
Community Survey 5-year estimates. 2017. Retrieved from: https://factfinder.

Page 10 of 10

census.gov/faces/nav/jsf/pages/community_facts.xhtml?src=bkmk. Accessed
16 Dec 2018.
78. Fenton JJ, Elmore JG, Buist DS, Reid RJ, Tancredi DJ, Baldwin LM.
Longitudinal adherence with fecal occult blood test screening in
community practice. Ann Fam Med. 2010;8(5):397–401.

